Search

Two hundreds patients suspected of acute myocardial infarction presenting to the hospital with a median symptom onset of 2.3 h (IQR 1.7-4.0 h) were enrolled in this study. The diagnostic performances of CardioDetect (R), a one-step immunotest for heart-type fatty acid-binding protein (H-FABP), and its combination with cardiac troponin I (cTnI) at admission and 2 h after admission, were compared with different cardiac markers. The H-FABP immunotest had better sensitivities (76.6% and 94.4%) than the other cardiac markers and better specificities (88.2% and 81.7%) than myoglobin at admission and 2 h after admission. Both sensitivity and negative predictive value increased to over 90.0% at 2 h after admission. The areas under the receiver operator characteristic curve for the combination of H-FABP with cTnI were the greatest at admission [0.834 (95% CI: 0.774-0.894)].

Two hundreds patients suspected of acute myocardial infarction presenting to the hospital with a median symptom onset of 2.3 h (IQR 1.7-4.0 h) were enrolled in this study. The diagnostic performances of CardioDetect (R), a one-step immunotest for heart-type fatty acid-binding protein (H-FABP), and its combination with cardiac troponin I (cTnI) at admission and 2 h after admission, were compared with different cardiac markers. The H-FABP immunotest had better sensitivities (76.6% and 94.4%) than the other cardiac markers and better specificities (88.2% and 81.7%) than myoglobin at admission and 2 h after admission. Both sensitivity and negative predictive value increased to over 90.0% at 2 h after admission. The areas under the receiver operator characteristic curve for the combination of H-FABP with cTnI were the greatest at admission [0.834 (95% CI: 0.774-0.894)].

Two hundreds patients suspected of acute myocardial infarction presenting to the hospital with a median symptom onset of 2.3 h (IQR 1.7-4.0 h) were enrolled in this study. The diagnostic performances of CardioDetect (R), a one-step immunotest for heart-type fatty acid-binding protein (H-FABP), and its combination with cardiac troponin I (cTnI) at admission and 2 h after admission, were compared with different cardiac markers. The H-FABP immunotest had better sensitivities (76.6% and 94.4%) than the other cardiac markers and better specificities (88.2% and 81.7%) than myoglobin at admission and 2 h after admission. Both sensitivity and negative predictive value increased to over 90.0% at 2 h after admission. The areas under the receiver operator characteristic curve for the combination of H-FABP with cTnI were the greatest at admission [0.834 (95% CI: 0.774-0.894)].

Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein abundant in heart muscle cells. It offers great potential as a sensitive biomarker for early diagnosis of acute myocardial infarction (AMI). Ninety-one patients presented to the Emergency Department suspected of AMI with a median symptom onset of 6 h (IQR 3-20 h), of which 75 (82.4\%) had AMI. The diagnostic performance of a point-of-care immunotest for H-FABP was compared with those of cardiac troponin T (cTnT), creatinine kinase MB (CK-MB), and myoglobin. The H-FABP immunotest was found to have a significant better sensitivity than the other markers and a better specificity than myoglobin and CK-MB. The H-FABP Immunotest gave the greatest area under the receiver operating characteristic (ROC) curve (0.864) for those admitted within 6 h after the onset of symptoms; whereas, cTnT gave the greatest area under the ROC curve (0.936) for those admitted 6-24 h. The H-FABP was also found to be the most efficient marker to diagnose patients suspected of AMI without ST-elevation and with a negative cTnT. Early detection of H-FABP using the point-of-care immunotest in patients suspected of AMI may allow more accurate targeting of appropriate therapy and considerable cost savings than the current diagnostic tests.

Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein abundant in heart muscle cells. It offers great potential as a sensitive biomarker for early diagnosis of acute myocardial infarction (AMI). Ninety-one patients presented to the Emergency Department suspected of AMI with a median symptom onset of 6 h (IQR 3-20 h), of which 75 (82.4\%) had AMI. The diagnostic performance of a point-of-care immunotest for H-FABP was compared with those of cardiac troponin T (cTnT), creatinine kinase MB (CK-MB), and myoglobin. The H-FABP immunotest was found to have a significant better sensitivity than the other markers and a better specificity than myoglobin and CK-MB. The H-FABP Immunotest gave the greatest area under the receiver operating characteristic (ROC) curve (0.864) for those admitted within 6 h after the onset of symptoms; whereas, cTnT gave the greatest area under the ROC curve (0.936) for those admitted 6-24 h. The H-FABP was also found to be the most efficient marker to diagnose patients suspected of AMI without ST-elevation and with a negative cTnT. Early detection of H-FABP using the point-of-care immunotest in patients suspected of AMI may allow more accurate targeting of appropriate therapy and considerable cost savings than the current diagnostic tests.

Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein abundant in heart muscle cells. It offers great potential as a sensitive biomarker for early diagnosis of acute myocardial infarction (AMI). Ninety-one patients presented to the Emergency Department suspected of AMI with a median symptom onset of 6 h (IQR 3-20 h), of which 75 (82.4\%) had AMI. The diagnostic performance of a point-of-care immunotest for H-FABP was compared with those of cardiac troponin T (cTnT), creatinine kinase MB (CK-MB), and myoglobin. The H-FABP immunotest was found to have a significant better sensitivity than the other markers and a better specificity than myoglobin and CK-MB. The H-FABP Immunotest gave the greatest area under the receiver operating characteristic (ROC) curve (0.864) for those admitted within 6 h after the onset of symptoms; whereas, cTnT gave the greatest area under the ROC curve (0.936) for those admitted 6-24 h. The H-FABP was also found to be the most efficient marker to diagnose patients suspected of AMI without ST-elevation and with a negative cTnT. Early detection of H-FABP using the point-of-care immunotest in patients suspected of AMI may allow more accurate targeting of appropriate therapy and considerable cost savings than the current diagnostic tests.